India Fondaparinux Market Size & Outlook, 2026-2034


India Fondaparinux Market Insights

  • As per Reed Intelligence insights, the India Fondaparinux Market stood at USD 58.75 Million in 2025 and is anticipated to grow to USD 111.61 Million by 2034.
  • The India market is expected to advance at a CAGR of 7.38% from 2026 through 2034.
  • In 2025, Deep Vein Thrombosis accounted for the highest share of the Indication market size.
  • During the forecast period, Pulmonary Embolism is set to register the highest growth, making it the most lucrative Indication segment.

Other Key Findings


  • In 2025, India accounted for 3.97% of the global Fondaparinux Market size.
  • By 2034, United States is expected to lead the global Fondaparinux Market in terms of market size.
  • Within Asia Pacific, China is projected to dominate the regional Fondaparinux Market size by 2034.
  • Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 33.56 Million by 2034.

Report Summary

Report Scope Details
Base Year for Study 2025
Study Period 2022-2034
Historical Period 2022-2024
Forecast Period 2026-2034
Market Size In 2025 USD 58.75 Million
Market Size In 2034 USD 111.61 Million
Largest segment Deep Vein Thrombosis
Units Revenue in USD Million
CAGR 7.38% (2026-2034)
Segmnetation Covered
Indication
  1. Deep Vein Thrombosis
  2. Pulmonary Embolism
  3. Acute Coronary Syndrome
  4. Venous Thromboembolism Prevention
Distribution Channel
  1. Hospital Pharmacies
  2. Retail Pharmacies
  3. Online Pharmacies
End Use
  1. Hospitals
  2. Specialty Clinics
  3. Ambulatory Surgical Centers
  4. Homecare Settings
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends